On June 28, 2022 the USPTO issued a Notice of Allowance for Application 16610991 - pending receipt of the applicable fees. Today August 31, 2022 the USPTO has posted that they have received the fees.
In the near(?) future there should be notice that the patent number is being issued.
"VACCINE CONTAINING CANCER CELLS INACTIVATED BY PHOTODYNAMIC TREATMENT WITH METAL-BASED COORDINATION COMPLEXES, AND IMMUNOTHERAPY METHOD USING SAME"
I am not sure that this vaccine patent has anything to do with what is going on in the Manitoba lab re Dr. Coombs, et al.
This is the abstract from the above application:
Abstract A method for treating a tumor in a patient by administering to the patient an immunogenic composition including antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, wherein the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration and the metal-based coordination complex having a specified formula. An immunogenic composition and a method for preparing it are also disclosed.
Another excerpt:
BACKGROUND OF THE INVENTION
1. Field of Invention
[0001] This invention relates to immunotherapy and more particularly to the combination of immunotherapy and photodynamic therapy.
2. Description of Related Art
[0002] Immunotherapy is recognized as a promising method for treating cancer with much as yet untapped potential. According to a 2016 recent press release from the USPTO regarding the "Cancer Moonshot" initiative, approximately 900 cancer immunotherapy applications are received annually by the USPTO.
[0003] One such application is US 20070025958 A1, which discloses compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. The compositions comprise an effective amount of a cytokine mixture, which acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen.
[0004] US 20150093416 A1 discloses autologous anti-cancer vaccines, wherein tumor cells are excised from a patient, implanted and grown in an immune-compromised animal. The resulting tumor tissue is harvested from the animal, inactivated by gamma radiation and incorporated into a vaccine composition for reinjection into the patient.
[0005] Photodynamic therapy (PDT) is another treatment modality showing much promise in the treatment of cancer. The development of new photodynamic compounds (PDCs or photosensitizers, PSs) for photodynamic therapy (PDT) has been increasingly focused on metallosupramolecular complexes derived from metals. For example, WO 2013158550 A1 and WO 2014145428 A2 disclose metal-based PDCs useful as in vivo diagnostic agents, as therapeutic agents for treating or preventing diseases that involve unwanted and/or hyperproliferating cell etiology, including cancer, as agents for treating infectious diseases, and as agents for pathogen disinfection and/or sterilization. U.S. Pat. No. 6,962,910, U.S. Pat. No. 7,612,057, U.S. Pat. No. 8,445,475 and U.S. Pat. No. 8,148,360 disclose supramolecular metal complexes capable of cleaving DNA when irradiated low energy visible light with or without molecular oxygen.
and
BRIEF SUMMARY OF THE INVENTION
[0009] A first aspect of the invention is a method for treating a tumor in a patient, said method comprising administering to the patient an immunogenic composition comprising antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, wherein the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration and the metal-based coordination complex.......